Date: 2015-10-01
Type of information: Publication of results in a medical journal
phase:
Announcement: publication of results in Clinical Cancer Research
Company: Kite Pharma (USA - CA)
Product: T cell receptor (TCR) product candidate targeting HPV-16 E6
Action
mechanism: cell therapy/immunotherapy product
Disease:
Therapeutic area: Cancer - Oncology
Country:
Trial
details:
Latest
news: * On October 1, 2015, Kite Pharma, a clinical-stage biopharmaceutical company focused on developing engineered autologous cell therapy (eACT™) products for the treatment of cancer, announced the publication of non-clinical findings describing the discovery and characterization of a novel T cell receptor (TCR) product candidate targeting HPV-16 E6. The findings published online by Clinical Cancer Research (doi:10.1158/1078-0432.CCR-14-3341), show that this TCR is highly selective and has high affinity for the HPV-16 E6, an oncoprotein that is associated with the majority of HPV-mediated cancers. The study also showed T cells engineered with HPV-16 E6 TCR selectively destroyed HPV-16 positive tumor cells. The National Cancer Institute (NCI) is conducting a Phase 1/2 clinical trial of this TCR product candidate under a Cooperative Research and Development Agreement (CRADA) between Kite and the NCI. \"HPV-16 E6 is a viral oncogene that is causally associated with cervical and other HPV-related cancers. Because E6 protein is expressed in cancer cells and absent in normal, healthy tissues, a TCR product candidate with high selectivity for this oncogene has the potential to become a novel cellular therapy directed against HPV-16 positive cancers,\" commented David Chang , M.D., Ph.D., Executive Vice President R&D and Chief Medical Officer. In December 2014 , Kite signed an exclusive, worldwide license with the National Institutes of Health (NIH) for the rights to develop and commercialize intellectual property related to TCR-based product candidates directed against HPV-16 E6 and E7 oncoproteins for the treatment of HPV-related cancers. Kite expects to file an IND for a Company-sponsored clinical trial of HPV-16 E6 TCR product candidate in the first half of 2016.
